Mebicar

Legal status
Legal status|

* US: Not approved

Identifiers

IUPAC name

* 1,3,4,6-Tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione

CAS Number|

* 10095-06-4

PubChem CID|

* 122282

ChemSpider|

* 109042

E number| {{#property:P628}}
ECHA InfoCard| {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula| C8H14N4O2
Molar mass| 198.222 g/mol
3D model (JSmol)|

* Interactive image

SMILES

* CN1C2C(N(C1=O)C)N(C(=O)N2C)C

InChI

* InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3

* Key:XIUUSFJTJXFNGH-UHFFFAOYSA-N

WikiDoc Resources for Mebicar

Articles

Most recent articles on Mebicar

Most cited articles on Mebicar

Review articles on Mebicar

Articles on Mebicar in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mebicar

Images of Mebicar

Photos of Mebicar

Podcasts & MP3s on Mebicar

Videos on Mebicar

Evidence Based Medicine

Cochrane Collaboration on Mebicar

Bandolier on Mebicar

TRIP on Mebicar

Clinical Trials

Ongoing Trials on Mebicar at Clinical Trials.gov

Trial results on Mebicar

Clinical Trials on Mebicar at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mebicar

NICE Guidance on Mebicar

NHS PRODIGY Guidance

FDA on Mebicar

CDC on Mebicar

Books

Books on Mebicar

News

Mebicar in the news

Be alerted to news on Mebicar

News trends on Mebicar

Commentary

Blogs on Mebicar

Definitions

Definitions of Mebicar

Patient Resources / Community

Patient resources on Mebicar

Discussion groups on Mebicar

Patient Handouts on Mebicar

Directions to Hospitals Treating Mebicar

Risk calculators and risk factors for Mebicar

Healthcare Provider Resources

Symptoms of Mebicar

Causes & Risk Factors for Mebicar

Diagnostic studies for Mebicar

Treatment of Mebicar

Continuing Medical Education (CME)

CME Programs on Mebicar

International

Mebicar en Espanol

Mebicar en Francais

Business

Mebicar in the Marketplace

Patents on Mebicar

Experimental / Informatics

List of terms related to Mebicar

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Overview

[edit | edit source]

Mebicar (mebicarum) is an anxiolytic medication produced by Latvian pharmaceutical company Olainfarm and sold in the Russian Federation under the brand name Adaptol.[1] It is not approved for use in the United States or European Union.

Mebicar has an effect on the structure of limbic-reticular activity, particularly on hypothalamus emotional zone, as well as on all 4 basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, increases the brain serotonin level, and does not elicit cholinolytic action.[2]

Mebicar purportedly has anti-anxiety (anxiolytic) properties.[2][3][4][5][6] It is also used to aid smoking cessation.[1] In addition Mebicar may be useful in the treatment of ADHD symptoms.[7] In contrast with typical anxiolytic medication like benzodiazepines Mebicar is non-habit forming, non-sedating and does not impair motor function.[3][1]

## References

[edit | edit source]

1. ↑ 1.0 1.1 1.2 Adaptol product summary http://olainfarm.lv/en/prescription-drugs/adaptol-3
2. ↑ 2.0 2.1 Val'Dman, AV; Zaikonnikova, IV; Kozlovskaia, MM; Zimakova, IE (1980). "Characteristics of the psychotropic spectrum of action of mebicar". Biulleten' eksperimental'noi biologii i meditsiny. 89 (5): 568–70. PMID 6104993.
3. ↑ 3.0 3.1 Val'Dman, A. V.; Zaikonnikova, I. V.; Kozlovskaya, M. M.; Zimakova, I. E. (1980). "A study of the spectrum of psychotropic action of mebicar". Bulletin of Experimental Biology and Medicine. 89 (5): 621. doi:10.1007/BF00835799.
4. ↑ Mkrtchian, VR; Kozhokova, LZ (2012). "Adaptol--verges of possible". Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy (5): 125–33. PMID 23534281.
5. ↑ Chutko, LS; Rozhkova, AV; Sidorenko, VA; Surushkina, SIu; Tursunova, KB (2012). "Generalized anxiety disorder: Psychosomatic aspects and treatment approaches". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 112 (1): 40–4. PMID 22678674.
6. ↑ Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Kuzovenkova, MP (2010). "Asthenic disorders in children". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 110 (11 Pt 1): 26–9. PMID 21183919.
7. ↑ Chutko, LS; Surushkina, SIu; Nikishena, IS; Iakovenko, EA; Anisimova, TI; Sergeev, AV (2009). "Adaptol in the treatment of ADHD". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 109 (8): 45–8. PMID 19738569.

Template:Anxiolytics
*[US]: United States
*[CID]: Compound ID